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1Preeclampsia and fetal growth restriction (FGR) affect 3% to 5% of all pregnancies. Both are significant contributors of 
maternal and perinatal morbidity and mortality.1,2 Preeclampsia 
is characterized by de novo hypertension in pregnancy and 
maternal organ dysfunction in the form of renal, hepatic, clot-
ting, or neurological abnormalities and FGR.3 FGR describes a 
fetus that fails to achieve its genetic growth potential, usually 
diagnosed by a statistical deviation of fetal size from popula-
tion-based standard in combination with functional changes in 
fetal and placental circulation.4,5
Although the pathogenic mechanisms of preeclampsia 
and FGR remain unclear, underlying causes are thought to 
overlap because of both conditions commonly occurring 
together. The most popular hypothesis is that of defective 
placental invasion in early pregnancy,6–9 and for this reason, 
both disorders are commonly ascribed within the umbrella 
term: maternal placental syndromes.10 This concept has 
largely arisen as the placenta has to be present for both disor-
ders to develop and resolves with delivery of the placenta.11 
Furthermore, placentas from affected pregnancies are reported 
to have characteristic histological abnormalities (incomplete 
invasion of maternal spiral arteries, acute atherosis, villous 
ischemia, and hypovascularity).12 However, the placental ori-
gins hypothesis has some inconsistencies.11,13 One third of 
placentas from pregnancies affected by preeclampsia at term, 
and ≈26% of placentas from FGR pregnancies have normal 
histological appearances.14–16 Preeclampsia can also present 
de novo in the postnatal period after the placenta has been 
delivered.17
Recent epidemiological observations suggest that mater-
nal cardiovascular function may play an important role in 
these disorders. Women affected by preeclampsia/FGR have 
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Abstract—Preeclampsia and fetal growth restriction during pregnancy are associated with increased risk of maternal 
cardiovascular disease later in life. It is unclear whether this association is causal or driven by similar antecedent risk 
factors. Clarification requires recruitment before conception which is methodologically difficult with high attrition rates 
and loss of outcome numbers to nonconception/miscarriage. Few prospective studies have, therefore, been adequately 
powered to address these questions. We recruited 530 healthy women (mean age: 35.0 years) intending to conceive 
and assessed cardiac output, cardiac index, stroke volume, total peripheral resistance, mean arterial pressure, and heart 
rate before pregnancy. Participants were followed to completion of subsequent pregnancy with repeat longitudinal 
assessments. Of 356 spontaneously conceived pregnancies, 15 (4.2%) were affected by preeclampsia and fetal growth 
restriction. Women who subsequently developed preeclampsia/fetal growth restriction had lower preconception cardiac 
output (4.9 versus 5.8 L/min; P=0.002) and cardiac index (2.9 versus 3.3 L/min per meter2; P=0.031) while mean 
arterial pressure (87.1 versus 82.3 mm Hg; P=0.05) and total peripheral resistance (1396.4 versus 1156.1 dynes sec 
cm−5; P<0.001) were higher. Longitudinal trajectories for cardiac output and total peripheral resistance were similar 
between affected and healthy pregnancies, but the former group showed a more exaggerated fall in mean arterial 
pressure in the first trimester, followed by a steeper rise and a steeper fall to postpartum values. Significant relationships 
were observed between cardiac output, total peripheral resistance, and mean arterial pressure and gestational epoch. 
We conclude that in healthy women, an altered prepregnancy hemodynamic phenotype is associated with the 
subsequent development of preeclampsia/fetal growth restriction.  (Hypertension. 2018;72:00-00. DOI: 10.1161/
HYPERTENSIONAHA.118.11092.) • Online Data Supplement
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persistent postpartum abnormal cardiovascular function in 
the form of asymptomatic echo-diagnosed heart failure,18,19 
increased risk of developing hypertensive disease after preg-
nancy, and a long-term increased risk of developing or dying 
from cardiovascular disease later in life.20,21 It is still unclear 
whether preeclampsia/FGR initiate damage to the mother’s 
cardiovascular system which then lead to a higher risk of 
later-life cardiovascular disease or whether preeclampsia/
FGR and cardiovascular disorders share common antecedent 
risk factors.22
The role of prepregnancy maternal cardiovascular 
function has not been comprehensively investigated pri-
marily because of the logistical difficulty of recruiting a 
healthy preconception cohort of women, many of whom 
will be naive to medical services. Previous studies of car-
diovascular function before pregnancy used retrospective 
data linkage from epidemiological and birth registries22 
or took postnatal assessments as surrogate prepregnancy 
measures.23,24
Therefore, to determine whether women who develop pre-
eclampsia and FGR show hemodynamic differences before 
pregnancy, we prospectively assessed cardiovascular hemo-
dynamics in healthy women from before pregnancy and fol-
lowed subsequent pregnancy outcomes.
Materials and Methods
Analytic methods, materials, and data that support the findings of 
this study are available from the corresponding author on reasonable 
request.
We conducted a prospective cohort study of healthy women in-
tending to conceive. As prospective preconception studies are meth-
odologically complex, we conducted and published a pilot study 
(2010–2012, Cambridge) to assess the feasibility of recruitment, 
retention, and obtaining sufficient pregnancy outcomes after ac-
counting for conception and spontaneous pregnancy loss rate.25 After 
successful completion of the feasibility phase, the main study (2014–
2017, London) was undertaken, which, for the assessments that we 
report, had an identical protocol to the feasibility study. Both studies 
received local site research authority approval and ethical approval 
from National Research Ethics Committees (reference numbers: 10/
H0304/28 and 14/ES/1046).
All participants had an initial study visit to undergo initial car-
diovascular hemodynamic assessments (detailed below in study 
protocol). Participants were then given 12 months to conceive a 
pregnancy. Those who conceived within study timeline had further 
follow-up through pregnancy: 2 visits in the first trimester (6 and 10 
weeks gestation), once in the second trimester (22 weeks gestation), 
once in the third trimester (34 weeks gestation), and at 6 to 10 weeks 
postpartum. Participant study timeline is illustrated in Figure 1. At 
each visit, hemodynamic assessments were repeated, thus providing 
longitudinal assessments for individual participants. At the end of 
pregnancy, participants were analyzed based on whether the preg-
nancy was affected by preeclampsia and FGR or unaffected preg-
nancy. All diagnoses and management of preeclampsia/FGR were 
made by the participant’s healthcare provider without involvement 
of the research team.
Recruitment and Study Entry Criteria
Healthy women planning a pregnancy were recruited via local and 
social media platforms and poster distributions to local general prac-
tice surgeries, community centers, hospitals, and universities in the 
London area. Those between the ages of 18 and 44 years who planned 
to conceive within 12 months of study entry were eligible. Women 
with a body mass index >35, current smokers, with preexisting con-
ditions of essential hypertension (defined as systolic >130 mm Hg 
and diastolic >90 mm Hg), renal disease, diabetes mellitus, thrombo-
philia, polycystic ovarian syndrome, and irregular menstrual cycles 
(>42 days cycle length) were excluded. Those pursuing conception 
using artificial reproductive technology (ovarian reserve stimulation, 
in-vitro fertilization) were also excluded.
Sample Size
Suboptimal physiological cardiac output (CO) increments (to the 
degree of 0.7 L/min) in the first trimester have been reported in asso-
ciation with recurrence of preeclampsia/FGR in a subsequent preg-
nancy,23,24,26 therefore preconception CO was selected as primary 
measure. Taking a conservative approach of detecting a smaller dif-
ference in CO of 0.5 L/min, at 80% power with 2-tailed α of 0.05, 196 
unaffected pregnancies and 12 pregnancies affected by preeclampsia/
FGR were required to power the study.
Based on conception and pregnancy loss data from the feasibil-
ity study, we predicted that at least 60% of women would conceive 
within 12 months.25 We planned to recruit 500 women, predicted to 
result in ≈300 pregnancies, with a rolling recruitment target taking 
into account real-time pregnancy rates. Accounting for 25% pro-
portional loss from miscarriage or chromosomal anomalies, and 
lost to study follow-up of ≈10%, 196 participants were projected 
to have viable pregnancies. Based on the incidence of preeclamp-
sia and FGR (3% each), ≈12 pregnancies would be affected by 
preeclampsia/FGR.
Study Protocol
At the first study visit (preconception), participants were requested 
to refrain from caffeinated drinks at least 4 hours before their assess-
ments. Baseline demographics and medical history including obstetric 
history were taken, and participant height and weight measured. All 
assessments were performed in a quiet temperature controlled room 
by 2 trained investigators. Participants were given a digital fertility 
monitor (Advanced Fertility Monitor, SPD Development Company 
Ltd) to track their menstrual cycles for 12 months, which allowed 
more accurate gestation specific study follow-up to be arranged based 
on dates of ovulation and first positive pregnancy testing (taken to 
relate to day of embryonic implantation27).
Cardiovascular function assessments were initiated after 10 
minutes of rest in the left lateral supine position. Brachial blood 
pressure (BP) and heart rate were measured in the right arm us-
ing an automated sphygmomanometer (Omron-M7) which has been 
validated for use in pregnancy using standard cuff size according 
to the arm circumference of the woman.28 All measurements were 
performed in duplicate.
Mean arterial pressure (MAP) was derived from the average 
of the 2 readings of systolic and diastolic pressures using the 
formula:
MAP = 1/3 systolic pressure  + 2/3 diastolic pressure( ) ( )
CO and stroke volume (SV) were assessed using a noninvasive, 
inert gas rebreathing technique, Innocor (Innovision A/S, Denmark) 
which has been validated against invasive assessments of cardiac 
function29 and utilized in previous obstetric cohort research. Innocor 
applies pulmonary gas exchange as a means of measuring the pul-
monary blood flow using a mixture. The subject continuously re-
breathes a gas mixture: 1% sulfur hexafluoride, 5% nitrous oxide, 
and 94% oxygen for 20 seconds, with a breathing rate of 20/min. 
Expired gases are sampled continuously and analyzed by an infrared 
photoacoustic gas analyzer for the determination of CO and SV. The 
rate of dissipation of nitrous oxide is proportional to the pulmonary Figure 1. Timeline of study participant visits. *Study visit.
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blood flow. A pulse oximeter simultaneously determines the heart 
rate from which SV (ie, the volume of blood ejected per heartbeat) 
is computed by the Innocor machine. Cardiac index was derived as 
CO divided by the participant’s body surface area (which is derived 
from height and weight).
Total Peripheral Vascular Resistance (TPR)
TPR was derived from the formula:
TPR dynes sec cm  = MAP mm Hg   80/CO L/min5• • −( ) ( ) ( )×
Clinical Outcomes
Clinical pregnancy outcomes including fetal scan reports conducted 
by maternity care providers were obtained from participant’s elec-
tronic maternity records. If these were not available, informations 
from their discharge letters were obtained from general practitio-
ner surgeries. The predefined clinical outcomes of interest was pre-
eclampsia and FGR.
Preeclampsia was defined using information prospectively as-
certained from participant’s medical records, as per the consensus 
statement from the International Society of Study of Hypertension 
in Pregnancy3:
New-onset hypertension (systolic BP >140 mmHg and/or 
diastolic BP >90 mmHg) with one or more of the follow-
ing: proteinuria, liver or renal function abnormalities, neu-
rological abnormalities, clotting disorders and/or placental 
insufficiency manifesting as FGR.
FGR was defined as per Delphi consensus statement30:
If FGR was diagnosed <32 weeks gestational age: Fetal ab-
dominal circumference (AC) or ultrasound estimated fetal 
weight (EFW) <3rd centile, or absent umbilical artery (UA) 
end diastolic flow (EDF) or AC/EFW <10th centile combined 
with uterine artery (UtA) pulsatility index (PI) >95th centile 
and/or UA PI >95th centile.
If FGR was diagnosed >32 weeks gestational age: AC/EFW 
<3rd centile or at least two out of three of the following: AC/
EFW <10th centile, AC/EFW crossing centiles >2 growth quar-
tiles, cerebro-placental ratio <5th centile or UA PI >95th centile.
Birth Weight Correlations
Aside from clinical outcomes as described above, we also related pre-
conception cardiovascular assessments to birth weight of subsequent 
pregnancy, which were obtained from participant’s health records. 
The birth weights were adjusted for gestational age to a z score 
using a program based on a population-based standards, using a fetal 
weight equation proposed by Hadlock et al31 with the customization 
proposed by Gardosi et al,32 and SD derived from the 2004 to 2008 
World Health Organization Global Survey on Maternal and Perinatal 
Health. Technical details of the z score calculator are described in the 
Appendix of Mikolajczyk et al.33
Statistical Analyses
Prepregnancy Group Comparisons
The distribution of each cardiovascular parameter was examined 
using the Shapiro-Wilk test. Prepregnancy cardiac measures were 
compared in women who subsequently developed preeclampsia/FGR 
and those who did not using a t test or a Mann-Whitney U test as 
appropriate. Continuous variables as reported as mean±SD (normal 
distribution) or median+interquartile range (non-normal distribu-
tion). All crude values were then adjusted using multivariable regres-
sion for maternal age, prepregnancy body mass index, and parity.
Birth Weight Correlations
Multivariable linear regression analysis was done to assess the rela-
tionship between prepregnancy cardiovascular parameters and birth 
weight z score using Stata14 (StataCorp, TX). These models were 
adjusted for potential confounders of maternal age, prepregnancy 
body mass index, parity, and gestational age at delivery (for birth 
weight z score).
Longitudinal Analyses
Longitudinal trajectories of each cardiovascular parameter from pre-
pregnancy to postpartum were analyzed using a multilevel linear 
spline model as describe in Tilling et al.34 In brief, to analyze the 
average pattern of change, each study visit was converted into a knot 
point, connected by linear splines. Knot points that did not show a 
marked difference in mean value from the preceding time point were 
excluded. Multilevel modeling was fitted to all available measures, 
and trajectory change per week was compared between the groups 
using a regression model.
Further, maximal information coefficient (MIC) as described in 
Reshef et al35 was used to capture a large range of associations (func-
tional or not) across the data set of all assessment and participant 
variables. Functional relationships were found between cardiovascu-
lar parameters and gestational age, and therefore an MIC score that 
roughly equals to the coefficient of determination (R2) of the data rel-
ative to the regression function was assigned. This allowed us to de-
termine nonlinear relationships between gestational status (ie, study 
visits at preconception, 6 weeks, 10 weeks, 22 weeks, 34 weeks, and 
postpartum) and change in cardiovascular parameters. Statistical sig-
nificance of the MIC value was further assessed through permutation 
testing.
Results
Preconception Demographics of Healthy Women 
Wishing to Conceive
A total of 530 women were recruited into a pilot and a follow-on 
main study (see Methods for details), and cumulative recruit-
ment flow chart is as shown in Figure 2. Mean participant age 
was 35.0 years (SD, 4.7), and mean time from assessment to con-
ception was 3.1 months. After withdrawals and exclusions, there 
were 494 women from which 356 pregnancies were conceived, 
a study conception rate of 71.2%. After excluding pregnancies 
affected by first trimester complications, multiple pregnancies, 
and a stillbirth (confirmed aneuploidy), 218 singleton pregnan-
cies were available for analyses. Of these, 15 pregnancies (6.8%) 
were affected by preeclampsia/FGR, consisting of 3 cases of 
preeclampsia, 8 cases of FGR, and 4 cases of preeclampsia 
occurring concurrently with FGR. Further characteristics of the 
study population by divided by subsequent pregnancy outcome 
are shown in Table 1, and details of pregnancies affected by pre-
eclampsia/FGR are reported in Table S1 in the online-only Data 
Supplement. Maternal age, parity, body mass index, and ethnic-
ity did not differ between affected and unaffected pregnancies, 
but women with a pregnancy complicated by preeclampsia/
FGR had a shorter gestational length and smaller babies.
Association of Preconception Cardiovascular 
Function and Subsequent Pregnancy Outcome
Preconception CO and cardiac index (CO adjusted for body 
surface area) were lower in women affected by preeclamp-
sia/FGR compared with women with an uncomplicated preg-
nancy, after adjusting for maternal characteristics (Table 2). 
The mean adjusted difference in our primary outcome mea-
sure, preconception CO was 0.8 L/min (95% confidence 
interval, −0.40 to −1.14). SV was also lower in women who 
subsequently developed preeclampsia/FGR.
Conversely, TPR was higher in women who developed 
preeclampsia/FGR, with a difference of 240.3 dynes·sec·cm−5 
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(95% confidence interval, −353.8 to −125.8). Components of 
peripheral BP measurements: systolic BP and MAP were dif-
ferent between the groups but not for diastolic BP. We per-
formed a subanalysis for nulliparous women (women who had 
not had a previous live or stillbirth n=123) to ascertain if the 
differences found in the group as a whole were still evident 
in women whose cardiovascular system was not previously 
subjected to the effects of a pregnancy. Differences remained 
in CO (5.73±1.1; 5.12±0.64 L/min; P=0.017), cardiac index 
(3.35±0.66, 3.05±0.387; P=0.048), and TPR (median=1140.74 
versus 1359.47; P=0.019) but not in peripheral BP and heart 
rate measurements.
Association of Preconception Cardiovascular 
Function and Birth Weight
We investigated the relationship between preconception 
cardiovascular parameters and birth weight, the latter 
being adjusted for gestation at delivery to derive a birth 
weight z score (Table S2). Associations were measured 
with R2 to determine approximation of the data to a fitted 
regression line.
For the primary outcome measure, prepregnancy CO 
showed a positive association (R2=0.07; P=0.022) with mean 
birth weight z score at term. A 1.0 L/min difference in CO was 
associated with a 0.164 increase in birth weight z score (95% 
confidence interval, 0.02–0.31), which translated to 53 g at 
term after adjustments for sex at delivery.
There were also small negative associations between 
MAP (R2=0.05), systolic BP (R2=0.05), heart rate (R2=0.04), 
and TPR (R2=0.07) while SV showed a positive corelation 
(R2=0.06) with birth weight.
Longitudinal Trajectories of Cardiovascular 
Parameters Between Those That Had a Subsequent 
Normal Pregnancy and Those That Developed 
Preeclampsia/FGR
Participants who conceived a pregnancy within study time-
line returned for follow-up visits during (6, 22, and 34 weeks 
gestation) and after pregnancy (6–10 weeks postpartum). 
Longitudinal changes in cardiovascular parameters from pre-
conception until postpartum were recorded. We compared 
individualized trajectories between the groups based on sub-
sequent pregnancy outcome and report here the main cardio-
vascular parameters of interests: CO, TPR, and MAP. 
The trajectories for CO and TPR were no different between 
gestational time points (Table 3).
Trajectories of MAP from preconception to postpartum 
between both groups were significantly different between 
Figure 2. Study flow chart. FGR indicates fetal 
growth restriction; and PE, preeclampsia.
Table 1. Baseline Maternal Characteristics and Birth Outcomes
Variable
Non-PE/FGR 
Pregnancies
PE/FGR 
Pregnancies P Value
n 203 (93%) 15 (7%) …
Maternal age, y 32.8 (3.9) 32.7 (4.1) 0.912
Maternal BMI, 
kg/m2
24.4 (5.9) 26.0 (3.5) 0.328
Nulliparity (%) 113 (55.7) 10 (66.7) 0.337
Ethnicity (n)
  White 156 10  
  Asian 22 5  
  Black Caribbean 13 0  
  Mixed 12 0  
Birth weight 3472.2 (454) 2341.53 (512.6) <0.001
Birth weight z 
score*
0.3 (−0.3 to 0.9) −1.7 (−2.1 to −0.9) <0.001
Gestation at 
delivery*(days by 
USS EDD)
279 (273 to 286) 268 (264 to 279) <0.001
BMI indicates body mass index; FGR, fetal growth restriction; PE, preeclampsia; 
and USS EDD, estimated due date determined by ultrasound scan.
*Non-normally distributed data. Normally distributed data presented as mean 
(SD), and non-normally distributed data presented as median (interquartile 
range).
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preconception to 6 weeks (controls: −0.5 U change/wk; pre-
eclampsia/FGR: −1.1 U change/wk; P=0.03), 6 to 22 weeks 
(controls: −0.2 U change/wk; preeclampsia/FGR: +0.2 U 
change/wk; P=0.001), as well as 34 weeks to postpartum 
(controls: +0.1 U change/wk; preeclampsia/FGR: −0.8 U 
change/wk; P<0.001).
Nonlinear relationship of the change in CO, TPR, and 
MAP with gestation was assessed using MIC. Permutation 
testing of MIC demonstrated statistically significant rela-
tionships between CO and TPR and gestational epochs from 
before pregnancy to the postpartum period in both outcome 
groups (Table S3). Change in MAP was only significantly 
related to gestation in those with normal pregnancy outcome. 
MIC scores across all 3 parameters was higher in those who 
developed preeclampsia/FGR (Figure 3).
Discussion
We report that before pregnancy, women who are subse-
quently affected by preeclampsia and FGR have different 
hemodynamic function compared with those with subsequent 
normal pregnancy outcome. Although none of the participants 
were classified as hypertensive nor had features of overt car-
diovascular disease before pregnancy, those that developed 
preeclampsia and FGR had a lower prepregnancy CO, higher 
resistance circulation, and higher BP.
It has been previously reported that higher prepregnancy 
BP (systolic of 130 mm Hg) is associated with a higher risk 
of developing preeclampsia.22 These observations were from 
a large study that linked BP measurements in a public health 
program to registered birth outcomes. Of note, the mean inter-
val between BP measurements and pregnancy was 3.5 to 4 
years, therefore events in the intervening period such as devel-
opment of essential hypertension, weight gain, or the use of 
artificial reproductive technologies for conception were unac-
counted for. To contrast, the mean interval between prepreg-
nancy assessments and pregnancy in our study was markedly 
shorter at 3 months and 3 days, and factors such as maternal 
anthropometrics and demographics just before index preg-
nancy were adjusted for in results.
We also demonstrate that the longitudinal trajectory of 
BP between our groups continued to differ significantly from 
preconception through the trimesters of pregnancy and up to 
the postpartum period. There is known to be a physiologi-
cal fall in BP in the first trimester of pregnancy. In women 
who subsequently develop preeclampsia/FGR, this drop in 
the first trimester is significantly more pronounced compared 
with controls, perhaps as a compensatory mechanism given 
the higher prepregnancy BP starting point for the affected 
group. This observation, despite being on a modest number 
of women who developed preeclampsia/FGR, has potential 
clinical implications. Women commonly have their baseline 
pregnancy measurement of BP in the latter half of the first 
trimester; as this BP might be unexpectedly low in women at 
risk of preeclampsia/FGR, their pregnancy could be paradoxi-
cally categorized as low risk. Beyond the first trimester, there 
was a significant increase in BP per week from the late first tri-
mester into the second trimester in women who subsequently 
develop preeclampsia/FGR. These women also experienced a 
more pronounced drop in BP from the third trimester to the 
postpartum period, which despite a late compensatory effect, 
does not reach the same levels as controls, resulting in a higher 
postpartum BP in women who developed preeclampsia/FGR. 
These findings suggest that targeted BP management or moni-
toring for affected women could be initiated in the late first 
trimester/early second trimester when incremental changes in 
BP are most marked.
Our findings of a relatively hypodynamic circulation with 
a lower CO and higher TPR in women who develop pre-
eclampsia/FGR lend credence to reports of hemodynamic 
dysfunction observed in the subclinical and clinical stage of 
preeclampsia and FGR.36–38 We find that these differences 
exist before pregnancy, preceding any sequalae of placental 
dysfunction, or perturbations exerted by preeclampsia/FGR 
on the maternal cardiovascular system. This raises the pos-
sibility of identifying a hemodynamic signature before preg-
nancy, in those women at risk of preeclampsia and FGR. A 
characteristic profile, integrated with more traditional cardio-
vascular risk factors such as body mass index, might identify 
Table 2.  Preconception Cardiovascular Parameters (Raw Data and Data Adjusted for Maternal BMI, Age, and Parity) Between Those That Subsequently Had a Pregnancy 
Affected by PE/FGR and Those That Had Unaffected Pregnancies
Preconception Parameter
Non-PE/FGR Pregnancy n=203 PE/FGR Pregnancy n=15 P Value
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
CO, L/min 5.8 (1.03) 5.8 (1.0) 5.0 (0.63) 4.9 (0.9) <0.001 0.002
CI, L/min per meter2 3.3 (0.6) 3.3 (0.6) 3.1 (0.42) 2.9 (0.6) 0.07 0.031
HR, bpm 67.3 (10.2) 67.3 (10.3) 66.4 (11.6) 66.2 (10.4) 0.781 0.685
SV, mL 82.2 (14.7) 82.2 (14.5) 74.4 (11.8) 73.9 (14.6) 0.027 0.047
TPR,* dynes·sec·cm−5 1152.5  
(1026.5–1292.8)
1156.1  
(776.2–1819.7)
1392.6  
(1283.0–1526.2)
1396.4  
(891.3–1737.8)
<0.001 <0.001
Systolic BP, mm Hg 113.6 (10.4) 113.6 (10.5) 116.7 (13.5) 119.2 (10.5) 0.31 0.05
Diastolic BP, mm Hg 66.1 (7.6) 66.2 (7.3) 69.7 (8.5) 67.0 (7.3) 0.86 0.158
MAP, mm Hg 82.3 (7.5) 82.3 (7.3) 86.4 (8.5) 87.1 (7.3) 0.19 0.04
BMI indicates body mass index; BP, blood pressure; CI, cardiac index; CO, cardiac output; FGR, fetal growth restriction; HR, heart rate; PE, preeclampsia; SV, stroke 
volume; and TPR, total peripheral resistance.
*Non-normally distributed data. Normally distributed data presented as mean (SD), and non-normally distributed data presented as median (interquartile range).
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women at risk of adverse outcome. Such models have been 
proposed after first trimester uterine artery Doppler and car-
diovascular assessment.39 The differences in CO and TPR in 
affected women also may inform targeted treatment in the 
form of manipulation of hemodynamic status. Women with 
preexisting hypertension, or those who subsequently develop 
preeclampsia, are commonly prescribed β-blocking agents as 
first line treatment40: these agents are negatively inotropic and 
may worsen an underlying low CO phenotype. Furthermore, 
the American Heart Association recognizes preeclampsia as a 
risk factor for future coronary heart disease and recommends 
lifestyle interventions after an affected pregnancy,41 and our 
findings support the rationale of exploring the initiation of 
these interventions before pregnancy.
We also find that prepregnancy CO is positively associ-
ated with birth weight at term. It is tempting to speculate that 
increasing CO could be beneficial in FGR pregnancies, a con-
dition for which there is currently no treatment. Plasma vol-
ume expanders and vasodilators have been shown to improve 
maternal CO and decreased TPR in pregnancies already 
affected by FGR and prolong gestation42 while prescribed 
aerobic therapy has been shown to increase venous reserve 
in women with a previous preeclampsia-affected pregnancy.43 
However, several constitutional and environmental factors 
contribute to birth weight,44,45 and it is unlikely that manipu-
lation of maternal hemodynamics alone is sufficient to over-
come all these factors.
We do not disregard an effect of the placenta in modu-
lation of the disease process of preeclampsia and FGR in 
pregnancy. The majority of our cases represent late-onset 
disease (conventionally taken as occurring beyond 34 weeks 
gestation), which occurs more frequently then early-onset 
disease.36 The phenotypes of late-onset disorders have 
greater associations with maternal factors such as dysregu-
lation of angiogenic and oxidative processes and preexisting 
medical comorbidities compared with the phenotypes that 
present early in pregnancy.46 Further examination of early-
onset disease may reflect a preferential placental component 
to its pathogenesis and would be an avenue to explore for 
future studies.
The main strength of our study was the prospective design 
and short interval between prepregnancy cardiovascular mea-
surements and pregnancy. Furthermore, we studied healthy 
women, hence the results were not biased by cardiovascular 
comorbidities, such as diabetes mellitus or preexisting hyper-
tension, in themselves independent prepregnancy risk factors 
for developing preeclampsia.
A limitation of our study is the modest numbers of cases of 
preeclampsia/FGR, totaling 15 pregnancies. This number was 
anticipated based on the population incidence of these dis-
orders, hence this study was adequately powered for the pri-
mary outcome, taking into account the large number initially 
recruited to anticipate for participants that did not conceive or 
conceived but miscarried. Our sample may have experienced a 
selection bias, in that healthier women who had an interest in 
medical research and healthy living were more likely to par-
ticipate in a study on cardiovascular and preconception health. 
Furthermore, we have considered both disorders together, as 
Table 3. Longitudinal Trajectories (Unit Change per Week) for CO (L/min per Week), TPR (Dynes·sec·cm−5/wk), and MAP (mm Hg/wk)
 
Non-PE/FGR 
Pregnancies
Pregnancies 
Affected by PE/FGR 95% CI P Value
Changes in supine CO L/min
  Mean at time zero (prepregnancy) 5.77 4.95 … …
  Mean change per week from preconception to 6 wk +0.13 +0.03 −1.3 to 0.1 0.87
  Mean change per week from 6 to 22 wk +0.01 +0.03 −0.02 to −0.6 0.41
  Mean change per week from 22 to 34 wk −0.39 −0.37 −0.05 to −0.8 0.70
  Mean change per week from 34 to postnatal −0.02 −0.09 −0.16 to 0.02 0.15
Changes in supine TPR, dynes·sec·cm−5
  Mean at time zero (prepregnancy) 1152.5 1392.6 … …
  Mean change per week from preconception to 6 wk −27.4 −42.8 −36.3 to 5.29 0.14
  Mean change per week from 6 to 22 wk −5.2 −4.3 −7.2 to 8.0 0.83
  Mean change per week from 22 to 34 wk +9.3 +10.6 −10.2 to 12.8 0.83
  Mean change per week from 34 to postnatal +6.7 +9.5 −14.4 to 20.0 0.75
Changes in supine MAP, mm Hg
  Mean at time zero (prepregnancy) 82.3 87.1 … …
  Mean change per week from preconception to 6 wk (inclusive) −0.5 −1.1 −1.2 to −0.1 0.03
  Mean change per week from 6 to 22 wk (inclusive) −0.2 +0.2 0.2 to 0.6 0.001
  Mean change per week from 22 to 34 wk (inclusive) +0.3 +0.4 −0.2 to 0.4 0.55
  Mean change per week from 34 to postnatal (inclusive) +0.12 −0.8 −1.4 to 0.5 <0.001
CI indicates confidence interval; CO, cardiac output; FGR, fetal growth restriction; MAP, mean arterial pressure; PE, preeclampsia; and TPR, total 
peripheral resistance.
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has been done in previous related studies.23,24,47 This method 
acknowledges the overlay between the 2 phenotypes (15% 
of pregnancies with FGR have superimposed preeclampsia,48 
and conversely, 12%–58% of preeclampsia pregnancies49,50 
are affected by FGR); in keeping with long-held belief that 
both are part of the same pathophysiological spectrum.51 It 
may not however address subtle differences in phenotypes of 
the conditions where underlying pathophysiology could be 
mutually exclusive.
Perspectives
We show that there are differences in hemodynamic pheno-
type from before pregnancy in healthy women who develop 
preeclampsia/FGR compared with those that do not develop 
these conditions. The women who develop preeclampsia/
FGR have a hemodynamic profile characterized by low CO, 
high vascular resistance, and higher prepregnancy BP. These 
women demonstrate a greater decline of BP in the first trimes-
ter compared with controls; this compensatory mechanism 
may mask their inclination to hypertensive disease later in 
pregnancy. The findings suggest that cardiovascular hemody-
namic dysfunction rather than placental maladaptation may 
play the initial pathogenic role in the origin of these disor-
ders, particularly in late-onset manifestations of preeclampsia/
FGR. From a clinical perspective, identifying a cardiovascular 
phenotype that is associated with future adverse pregnancy 
outcomes may be a useful target for prepregnancy screening 
and intervention. Future studies are needed to examine the 
feasibility of integrating maternal cardiovascular parameters 
into predictive models for preeclampsia/FGR and the pos-
sibility of manipulating maternal hemodynamics to improve 
pregnancy outcomes.
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What Is New?
•	 In healthy women, a low-output, high resistance hemodynamic pheno-
type from preconception is associated with developing preeclampsia and 
fetal growth restriction in pregnancy.
What Is Relevant?
•	Our findings may explain the link between pregnancy-specific disorders 
and increased risk of cardiovascular disease, including hypertension in 
later life.
•	Hemodynamic aberrations that we report are potential targets for precon-
ception intervention or tailored antihypertensive therapy in pregnancy.
Summary
A subset of healthy women have occult cardiovascular dysfunction 
which is associated with increased risk of developing preeclamp-
sia/fetal growth restriction in pregnancy. This study highlights the 
shift of understanding in the paradigm of these disorders, classi-
cally thought to originate from placental dysfunction.
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Table S1 Clinical details for 15 pregnancies affected by PE/FGR 
 
 
 
 
 
 
 
Maternal 
age 
Number of 
previous 
pregnancies 
(parity) 
Previous 
adverse 
outcome 
pregnancy 
Pregnancy 
outcome in study 
Gestation at 
delivery 
(completed 
weeks) 
36 0 - FGR 39 
39 1 FGR FGR 38 
30 1 PE  PE 38 
35 0 - FGR 39 
35 0 - FGR 40 
25 0 - PE + FGR 34 
36 0 - FGR 40 
32 0 - PE 40 
30 0 - FGR 38 
30 0 - PE + FGR 38 
37 0 - PE 40 
37 1 PE + FGR PE + FGR 29 
29 0 - FGR 35 
32 1 FGR FGR  39 
27 1 No PE + FGR 38 
  
Table S2 Multi-variable associations between pre-conception CV parameters and 
birth-weight z-score. Model 1: Crude values; Model 2: Values adjusted for maternal 
factors of age, parity and BMI 
 
 
 
 
 
 
 
 
 
  Mean diff 95%CI R2 P value 
Systolic BP 
(mmHg) 
Model 1 0.007 -0.02 – 0.001 0.002 0.516 
Model 2 -0.006 0.02 – 0.01 0.05 0.404 
Diastolic BP 
(mmHg) 
Model 1 0.01 -0.01 – 0.033 0.002 0.523 
Model 2 0.004 0.02 – 0.02 0.05 0.716 
MAP 
(mmHg) 
Model 1 0.009 -0.02 – 0.02 0.0002 0.823 
Model 2 -0.0012 -0.02 – 0.02 0.05 0.905 
HR 
 (bpm) 
Model 1 0.007 -0.02 – 0.01 0.0003 0.788 
Model 2 -0.0012 0.02 – 0.01 0.04 0.867 
CO  
(L/min) 
Model 1 0.178 0.01 – 0.29 0.02 0.040 
Model 2 0.164 0.02 – 0.31 0.07 0.022 
CI 
(L/min/m2) 
Model 1 0.014 -0.22 – 0.25 0.0001 0.905 
Model 2 0.0535 -0.18 – 0.30 0.04 0.663 
SV  
(L) 
Model 1 0.01 0.0 – 0.02 0.0203 0.036 
Model 2 0.0094 0.0 – 0.02 0.06 0.048 
TPR  
(dyness.sec.cm-5) 
Model 1 -0.0007 -0.001 - -0.0001 0.02 0.030 
Model 2 -0.001 -0.001 - -0.0001 0.07 0.012 
  
 
 
 
Table S3 Maximal information coefficient (MIC) scores for gestation and changes in 
CO (L/min), TPR (Dynes.sec.cm-5) and MAP (mmHg) 
 
 
 
 
 
 
 
 
 
 
 
Parameter Non PE/FGR pregnancies 
(n=203) 
PE/FGR pregnancies 
(n =15) 
MIC P value MIC P value 
CO 
(L/min) 
0.10 0.002 0.28 0.03 
TPR  
(Dynes.sec.cm-5) 
0.16 <0.001 0.33 0.02 
MAP 
(mmHg) 
0.13 <0.001 0.21 0.63 
